Evotec (EVO) Nominates First Preclinical Development Candidate from Almirall Alliance

Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy Before They Explode.

On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology. The program is aimed at developing new therapies for immune-mediated inflammatory skin diseases with significant unmet medical needs. Evotec SE (NASDAQ:EVO) said it will continue supporting the program toward IND submission through its INDiGO platform, which is designed to accelerate the transition from discovery through clinical readiness.

On April 30, 2026, Evotec SE (NASDAQ:EVO) also announced that it received two additional grants from the Gates Foundation for tuberculosis drug discovery and translation programs. The grants follow four earlier TB-related awards from the foundation and total approximately $4.9M over 25 months and $5M over 24 months. The company said the programs are intended to expand the pipeline of tuberculosis drug candidates and advance the most promising combinations toward clinical evaluation while helping reduce development risk.

Evotec (EVO) Nominates First Preclinical Development Candidate from Almirall Alliance

Earlier in April, H.C. Wainwright assumed coverage on Evotec SE (NASDAQ:EVO) with a Buy rating and a $7 price target. The firm said the company has been transitioning away from a more asset-heavy integrated structure toward a leaner and more capital-efficient operating model, adding that current share levels appear attractive for long-term investors.

Evotec SE (NASDAQ:EVO) operates as a drug discovery and development company across the United States, Europe, and other international markets.

While we acknowledge the risk and potential of EVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EVO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.